INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.14
+0.43%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $0.50
- Revenue estimate
- $115.4M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $1.14
- EPS estimate
- $0.44
- Revenue actual
- $119.6M
- Revenue estimate
- $111.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +192.3%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $38
- PT range
- $34 – $42
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $0.44 | $1.14 | Beat 161.47% | $119.6M |
| May 6, 2026 | $0.43 | $0.44 | Beat 2.33% | $98.0M |
| Feb 25, 2026 | $0.34 | $1.94 | Beat 470.59% | $114.6M |
| Nov 5, 2025 | $0.46 | $1.08 | Beat 134.78% | $107.8M |
| Aug 6, 2025 | $0.57 | $0.77 | Beat 35.09% | $100.3M |
| May 7, 2025 | $0.29 | $0.25 | Miss -13.79% | $88.6M |
| Feb 26, 2025 | $0.34 | $0.57 | Beat 67.65% | $91.8M |
| Jul 31, 2024 | $0.24 | $0.68 | Beat 183.33% | $103.4M |
| Feb 29, 2024 | $0.23 | $0.76 | Beat 230.43% | $89.3M |
| Nov 1, 2023 | $0.27 | $0.98 | Beat 262.96% | $67.3M |
| Aug 2, 2023 | $0.26 | $0.08 | Miss -69.23% | $81.0M |
| Feb 28, 2023 | $0.41 | $0.25 | Miss -39.02% | $65.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026